BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9502454)

  • 21. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group.
    Dupont H; Carbon C; Carlet J
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2028-33. PubMed ID: 10898671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
    Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
    Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group.
    Wolff M
    Antimicrob Agents Chemother; 1998 Jan; 42(1):28-36. PubMed ID: 9449256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
    Rossini F; Terruzzi E; Verga L; Larocca A; Marinoni S; Miccolis I; Giltri G; Isella M; Parma M; Pogliani EM
    Support Care Cancer; 2005 Jun; 13(6):387-92. PubMed ID: 15599778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia.
    Fowler RA; Flavin KE; Barr J; Weinacker AB; Parsonnet J; Gould MK
    Chest; 2003 Mar; 123(3):835-44. PubMed ID: 12628886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Basic and clinical studies on tazobactam/piperacillin in pediatric field].
    Motohiro T; Nagai K; Yamada T; Oki S; Yamada T; Yoshinaga Y; Tsumura N; Oda K; Sakata Y; Kato H; Imai S; Morita J; Matsuo Y; Ikezawa S; Takahgashi K; Fukuda T; Yamashita Y; Aramaki M; Hayashi M; Yamakawa R; Ono-E ; Tananari Y; Tsutsumi T; Hoshuyama A; Aida K
    Jpn J Antibiot; 1998 Jun; 51(6):413-31. PubMed ID: 9755831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
    Kollef MH; Nathwani D; Merchant S; Gast C; Quintana A; Ketter N
    Crit Care; 2010; 14(3):R84. PubMed ID: 20459721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
    Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS
    J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
    Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
    Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
    Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
    Yamamoto Y; Izumikawa K; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Tsukamoto M; Kakeya H; Yanagihara K; Yasuoka A; Kohno S
    J Infect Chemother; 2013 Apr; 19(2):291-8. PubMed ID: 23345050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients.
    Kobayashi R; Sato T; Nakajima M; Kaneda M; Iguchi A
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):270-3. PubMed ID: 19346879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy.
    Flidel-Rimon O; Friedman S; Gradstein S; Bardenstein R; Shinwell ES
    Acta Paediatr; 2003 Oct; 92(10):1205-7. PubMed ID: 14632339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
    Zengin E; Sarper N; Kılıç SC
    Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.
    Joshi M; Bernstein J; Solomkin J; Wester BA; Kuye O
    J Antimicrob Chemother; 1999 Mar; 43(3):389-97. PubMed ID: 10223595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.